Theravance Biopharma price target raised to $40 from $25 at BTIG

BTIG raised the firm’s price target on Theravance Biopharma (TBPH) to $40 from $25 and keeps a Buy rating on the shares. The firm is revisiting its annualized net price for ampreloxetine in nOH and lowering standalone operating expense assumptions to better reflect a rare disease launch, the analyst tells investors in a research note.